Patents by Inventor Joseph P. Lyssikatos

Joseph P. Lyssikatos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS
    Publication number: 20240228486
    Abstract: Provided herein are compounds and compositions for selective inhibition of PARP1 over PARP2, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as pancreatic, prostate, bladder, endometrial, lung, colorectal, ovarian, peritoneal, or breast cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 11, 2024
    Inventors: Joseph P. LYSSIKATOS, Li REN
  • Compounds, Compositions and Methods
    Publication number: 20240150376
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: August 10, 2023
    Publication date: May 9, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2
    Publication number: 20240116921
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 11, 2024
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
  • 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
    Publication number: 20240043420
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Application
    Filed: October 4, 2021
    Publication date: February 8, 2024
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
  • Inhibiting agents for bruton's tyrosine kinase
    Patent number: 11858926
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: January 2, 2024
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Substituted pyrimidines as LRKK2 inhibitors
    Patent number: 11840529
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 12, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions, and methods
    Patent number: 11834439
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
    Publication number: 20230382923
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Application
    Filed: May 15, 2023
    Publication date: November 30, 2023
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN, Qiang SU
  • 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
    Publication number: 20230382907
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
  • 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
    Patent number: 11807638
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: November 7, 2023
    Assignee: ENLIVEN INC.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren
  • Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
    Patent number: 11807649
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 7, 2023
    Assignee: EnLiven Therapeutics, Inc.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren, Qiang Su
  • 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
    Patent number: 11767321
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: September 26, 2023
    Assignee: ENLIVEN INC.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren
  • ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
    Publication number: 20230265098
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: August 24, 2023
    Inventor: Joseph P. LYSSIKATOS
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230227436
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 20, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • IMAGING METHODS USING DEUTERATED COMPOUNDS
    Publication number: 20230218782
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Application
    Filed: November 18, 2022
    Publication date: July 13, 2023
    Applicant: Genentech, Inc.
    Inventors: Jan MARIK, Joseph P. LYSSIKATOS, Simon Peter WILLIAMS
  • FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
    Publication number: 20230159557
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Application
    Filed: November 1, 2022
    Publication date: May 25, 2023
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN, Qiang SU
  • N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
    Publication number: 20230142839
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: September 8, 2022
    Publication date: May 11, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
  • INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
    Publication number: 20230147490
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: July 22, 2022
    Publication date: May 11, 2023
    Inventors: Brian T. HOPKINS, Bin MA, Robin PRINCE, Isaac MARX, Joseph P. LYSSIKATOS, Fengmei ZHENG, Matthew PETERSON, Daniel B. PATIENCE
  • 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
    Publication number: 20230130724
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Application
    Filed: December 13, 2022
    Publication date: April 27, 2023
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
  • 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
    Publication number: 20230065635
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Application
    Filed: October 4, 2021
    Publication date: March 2, 2023
    Inventors: Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN